Header Logo

Connection

Bruce Fireman to Vaccines, Synthetic

Back to Details
This is a "connection" page, showing publications Bruce Fireman has written about Vaccines, Synthetic.
Bruce Fireman
Connection Strength
0.578
Vaccines, Synthetic
  1. Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. N Engl J Med. 2023 Dec 14; 389(24):2245-2255.
    View in: PubMed
    Score: 0.228
  2. Recombinant Influenza Vaccine in Adults under 65 Years of Age. Reply. N Engl J Med. 2024 Mar 21; 390(12):1156.
    View in: PubMed
    Score: 0.058
  3. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.052
  4. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.051
  5. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022 04 01; 5(4):e228879.
    View in: PubMed
    Score: 0.051
  6. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.049
  7. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.049
  8. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatr Infect Dis J. 1993 Dec; 12(12):981-5.
    View in: PubMed
    Score: 0.028
  9. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J. 1991 Feb; 10(2):92-6.
    View in: PubMed
    Score: 0.006
  10. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J. 1991 Feb; 10(2):97-104.
    View in: PubMed
    Score: 0.006

© 2024 Kaiser Permanente